Key Highlights:
- Akums has developed a DCGI-approved clarithromycin + vonoprazan + amoxicillin combikit for treating H. pylori infection in adults.
- The 14-day, twice-daily regimen combines vonoprazan 20 mg, clarithromycin 500 mg and amoxicillin 1,000 mg, with the full amoxicillin dose provided in a single tablet.
- The formulation is designed to combine sustained gastric acid suppression with complementary antibacterial activity, while an organized treatment pack may help improve regimen clarity and convenience for patients.
Implications:
Akums’ DCGI‑approved vonoprazan + clarithromycin + amoxicillin combikit introduces a modern, P‑CAB‑based triple therapy for H. pylori in India at a time when guidelines are shifting away from older PPI‑based regimens due to rising antibiotic resistance and the need for more reliable acid suppression. By packaging a 14‑day, twice‑daily regimen with the full 1,000 mg amoxicillin dose in a single tablet, Akums is targeting better adherence and regimen clarity in a large, under‑treated H. pylori population, while strengthening its gastroenterology portfolio against both branded originators and other Indian players adopting vonoprazan‑based combinations.
Source: Express Pharma
